| __timestamp | Exelixis, Inc. | HUTCHMED (China) Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 50829000 | 26684000 |
| Thursday, January 1, 2015 | 57305000 | 29829000 |
| Friday, January 1, 2016 | 116145000 | 39578000 |
| Sunday, January 1, 2017 | 159362000 | 43277000 |
| Monday, January 1, 2018 | 206366000 | 48645000 |
| Tuesday, January 1, 2019 | 228244000 | 52934000 |
| Wednesday, January 1, 2020 | 293355000 | 61349000 |
| Friday, January 1, 2021 | 401715000 | 127125000 |
| Saturday, January 1, 2022 | 459856000 | 136106000 |
| Sunday, January 1, 2023 | 542705000 | 133175999 |
| Monday, January 1, 2024 | 492128000 |
In pursuit of knowledge
In the ever-evolving landscape of the pharmaceutical industry, effective cost management is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Exelixis, Inc. and HUTCHMED (China) Limited from 2014 to 2023. Over this period, Exelixis, Inc. has seen a staggering increase in SG&A expenses, growing by over 900%, reflecting its aggressive expansion and investment in operational capabilities. In contrast, HUTCHMED (China) Limited's expenses have increased by approximately 400%, indicating a more measured approach to growth.
These trends underscore the diverse strategies employed by these companies in navigating the competitive pharmaceutical market.
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and Opthea Limited
Exelixis, Inc. and ADMA Biologics, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Exelixis, Inc. or Iovance Biotherapeutics, Inc.
Selling, General, and Administrative Costs: Exelixis, Inc. vs BioCryst Pharmaceuticals, Inc.
CRISPR Therapeutics AG or HUTCHMED (China) Limited: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Veracyte, Inc. and HUTCHMED (China) Limited
Selling, General, and Administrative Costs: MorphoSys AG vs HUTCHMED (China) Limited
Operational Costs Compared: SG&A Analysis of Catalyst Pharmaceuticals, Inc. and HUTCHMED (China) Limited
HUTCHMED (China) Limited vs ImmunityBio, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: HUTCHMED (China) Limited vs Amphastar Pharmaceuticals, Inc. Trends and Insights
HUTCHMED (China) Limited or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of HUTCHMED (China) Limited and Viridian Therapeutics, Inc.